Ipsen: Strong start to the year drives FY guidance upgrade

BUY, Fair Value EUR52 vs. EUR46.5 (+9%)
News published on April Wednesday 29, 2015
Share on

Ipsen posted today very strong first quarter sales, driven by Speciality Care including Somatuline, up 25%. Revenue growth guidance for Speciality Care is upgraded for the year to 10-12% (from 8-10%) and the core operating margin for the group too, from 19-20% to 21-22% (50% for TasQ and 50% for underlying business). Our sequence of core EPSs is revised upwards and our FV increased.

For more information, please contact marketing@bryangarnier.com 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities